Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AEGR

AEGR (AEGR) Stock Price, News & Analysis

AEGR logo

About AEGR Stock (NASDAQ:AEGR)

Advanced Chart

Key Stats

Today's Range
$1.97
$1.97
50-Day Range
$1.97
$1.97
52-Week Range
$1.23
$10.85
Volume
N/A
Average Volume
635,262 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Receive AEGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter.

AEGR Stock News Headlines

Hedge Fund - Glenhill Advisors
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
See More Headlines

AEGR Stock Analysis - Frequently Asked Questions

AEGR (NASDAQ:AEGR) issued its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $1.14. AEGR's revenue for the quarter was down 39.9% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that AEGR investors own include Bristol-Myers Squibb (BMY), Allergan (AGN), Ford Motor (F), Gilead Sciences (GILD), NVIDIA (NVDA), Tesla (TSLA) and Ariad Pharmaceuticals (ARIA).

Company Calendar

Last Earnings
5/16/2016
Today
4/19/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AEGR
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

This page (NASDAQ:AEGR) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners